Julia Hinkel
Julia Hinkel has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Stephan Grabbe
Department of Dermatology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany
3 shared publications Caroline Mann
2 shared publications- Deniz Özistanbullu
Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
2 shared publications - Jakob Veeser2 shared publications
- Joanna Wegner
Department of Dermatology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany
2 shared publications - Klajdi Begaj
Hautklinik und Poliklinik Universitätsmedizin der Johannes Gutenberg‐Universität Mainz
2 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Evaluation of a Structured, Guideline-Based Digitally-Supported Multimodal Care Concept for People with Inflammatory Dermatoses (EsmeDerm): Protocol for a Multicentre Randomised Controlled Trial (Preprint)
BACKGROUND Chronic inflammatory skin diseases such as psoriasis and atopic dermatitis are associated with a substantial physical, psychological, and social burden. Despite the availability of evidence-based clinical guidelines, important gaps remain in the provision of coordinated, patient-centered, and multimodal care. OBJECTIVE To evaluate the effectiveness and implementation of a structured, multimodal digitally-supported care model for adults with psoriasis or atopic dermatitis compared with regular care. METHODS EsmeDerm is a German multicentre, two-arm, parallel-group, 1:1 randomized controlled trial embedded within a comprehensive evaluation framework for complex interventions. Adults with psoriasis or atopic dermatitis and a Dermatology Life Quality Index (DLQI) score ≥6 and a Hospital Anxiety and Depression Scale (HADS) total score ≥3 are eligible for participation. Participants are randomized to either an intervention group (IG), receiving multimodal care at a Center for Inflammatory Dermatoses (CiD), or a control group (CG), receiving regular care. Care delivery in the CiD is supported by a specially developed digital platform, the Inflammatory Dermatoses Assistant (iDA). From month 6 onward, participants in the CG also receive the physician-delivered CiD components; however, educational components delivered by trained medical assistants are not provided. Assessments are conducted at baseline and after 3, 6, 9, and 12 months. The primary endpoint is the absolute change in HADS score from baseline to month 6. Secondary outcomes include itch severity, health-related quality of life, self-management competence, modifiable risk factors, treatment satisfaction, and clinical disease severity. The planned sample size is 698 participants. Primary analyses are conducted according to the intention-to-treat principle, with exploratory per-protocol analyses performed as sensitivity analyses. Process and health economic evaluations complement the effectiveness evaluation to assess implementation, acceptability, and cost-effectiveness. RESULTS The study protocol has been approved by the Ethics Committee of the State Chamber of Physicians of Rhineland-Palatinate (Landesärztekammer Rheinland-Pfalz). The study employs digital informed consent procedures and pseudonymized data transfer for independent evaluation. Study conduct follows, where applicable, the principles of Good Clinical Practice, good practice recommendations for secondary data analyses, and the ethical principles of the Declaration of Helsinki. Recruitment started July 2026. Study findings will be disseminated through peer-reviewed publications and scientific conferences in accordance with consortium regulations and the recommendations of the International Committee of Medical Journal Editors (ICMJE). CONCLUSIONS EsmeDerm will provide evidence on the effectiveness and implementation of a structured, multimodal care model for patients with psoriasis or atopic dermatitis. The findings may inform the further development and integration of coordinated, patient-centred care into routine practice. CLINICALTRIAL DRKS00038738
- 28 October 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEvaluation of a Structured, Guideline-Based Digitally-Supported Multimodal Care Concept for People with Inflammatory Dermatoses (EsmeDerm): Protocol for a Multicentre Randomised Controlled Trial (Preprint)
BACKGROUND Chronic inflammatory skin diseases such as psoriasis and atopic dermatitis are associated with a substantial physical, psychological, and social burden. Despite the availability of evidence-based clinical guidelines, important gaps remain in the provision of coordinated, patient-centered, and multimodal care. OBJECTIVE To evaluate the effectiveness and implementation of a structured, multimodal digitally-supported care model for adults with psoriasis or atopic dermatitis compared with regular care. METHODS EsmeDerm is a German multicentre, two-arm, parallel-group, 1:1 randomized controlled trial embedded within a comprehensive evaluation framework for complex interventions. Adults with psoriasis or atopic dermatitis and a Dermatology Life Quality Index (DLQI) score ≥6 and a Hospital Anxiety and Depression Scale (HADS) total score ≥3 are eligible for participation. Participants are randomized to either an intervention group (IG), receiving multimodal care at a Center for Inflammatory Dermatoses (CiD), or a control group (CG), receiving regular care. Care delivery in the CiD is supported by a specially developed digital platform, the Inflammatory Dermatoses Assistant (iDA). From month 6 onward, participants in the CG also receive the physician-delivered CiD components; however, educational components delivered by trained medical assistants are not provided. Assessments are conducted at baseline and after 3, 6, 9, and 12 months. The primary endpoint is the absolute change in HADS score from baseline to month 6. Secondary outcomes include itch severity, health-related quality of life, self-management competence, modifiable risk factors, treatment satisfaction, and clinical disease severity. The planned sample size is 698 participants. Primary analyses are conducted according to the intention-to-treat principle, with exploratory per-protocol analyses performed as sensitivity analyses. Process and health economic evaluations complement the effectiveness evaluation to assess implementation, acceptability, and cost-effectiveness. RESULTS The study protocol has been approved by the Ethics Committee of the State Chamber of Physicians of Rhineland-Palatinate (Landesärztekammer Rheinland-Pfalz). The study employs digital informed consent procedures and pseudonymized data transfer for independent evaluation. Study conduct follows, where applicable, the principles of Good Clinical Practice, good practice recommendations for secondary data analyses, and the ethical principles of the Declaration of Helsinki. Recruitment started July 2026. Study findings will be disseminated through peer-reviewed publications and scientific conferences in accordance with consortium regulations and the recommendations of the International Committee of Medical Journal Editors (ICMJE). CONCLUSIONS EsmeDerm will provide evidence on the effectiveness and implementation of a structured, multimodal care model for patients with psoriasis or atopic dermatitis. The findings may inform the further development and integration of coordinated, patient-centred care into routine practice. CLINICALTRIAL DRKS00038738
- Open Access
- 29 April 2026
- Published by JMIR Publications Inc. in JMIR Infodemiology
Online Search Behavior Related to Psoriasis in Germany: Infodemiology Study Using Google Ads and Google Trends (Preprint)
- 29 April 2026
- Published by JMIR Publications Inc. in JMIR Infodemiology
Open AccessOnline Search Behavior Related to Psoriasis in Germany: Infodemiology Study Using Google Ads and Google Trends (Preprint)
- Open Access
- 29 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
The Digital Footprint of Psoriasis: Popularity of Simple Solutions vs. Neglect of Advanced Therapies (Preprint)
BACKGROUND Psoriasis causes considerable physical and psychosocial burden. Despite the availability of effective topical and systemic treatments, real-world care appears to be characterized by undertreatment, and many patients have limited knowledge of modern therapeutic options. Online search behavior can provide valuable insights into unmet informatiThis study aims to analyze psoriasis-related online search behavior in Germany to identify knowledge gaps and assess whether commonly searched topics reflect guideline-recommended care.onal needs, concerns, and treatment interests at the population level. OBJECTIVE This study aims to analyze psoriasis-related online search behavior in Germany to identify knowledge gaps and assess whether commonly searched topics reflect guideline-recommended care. METHODS Google Ads data for psoriasis-related search terms in Germany from May 2022 to April 2024 were systematically evaluated by topic and search volume. In addition, Google Trends data from 2014 to 2024 were analyzed to assess long-term trends. RESULTS The colloquial term “Schuppenflechte” was searched far more frequently than “psoriasis.” In total, 1,775 search terms were identified, corresponding to up to 70 million searches over two years. Almost half of all location-specific queries referred to the head region, consistent with guideline criteria for systemic therapy. In contrast, interest in evidence-based treatments was low. Searches focused mainly on home remedies (44.5%), while biologics accounted for only 0.4%. CONCLUSIONS Future information campaigns and educational materials should use the lay term “Schuppenflechte”. Online search behavior reveals potential gaps in awareness of guideline-recommended therapies for psoriasis. These findings highlight the need for better patient-oriented, evidence-based digital education.
- 29 April 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Digital Footprint of Psoriasis: Popularity of Simple Solutions vs. Neglect of Advanced Therapies (Preprint)
BACKGROUND Psoriasis causes considerable physical and psychosocial burden. Despite the availability of effective topical and systemic treatments, real-world care appears to be characterized by undertreatment, and many patients have limited knowledge of modern therapeutic options. Online search behavior can provide valuable insights into unmet informatiThis study aims to analyze psoriasis-related online search behavior in Germany to identify knowledge gaps and assess whether commonly searched topics reflect guideline-recommended care.onal needs, concerns, and treatment interests at the population level. OBJECTIVE This study aims to analyze psoriasis-related online search behavior in Germany to identify knowledge gaps and assess whether commonly searched topics reflect guideline-recommended care. METHODS Google Ads data for psoriasis-related search terms in Germany from May 2022 to April 2024 were systematically evaluated by topic and search volume. In addition, Google Trends data from 2014 to 2024 were analyzed to assess long-term trends. RESULTS The colloquial term “Schuppenflechte” was searched far more frequently than “psoriasis.” In total, 1,775 search terms were identified, corresponding to up to 70 million searches over two years. Almost half of all location-specific queries referred to the head region, consistent with guideline criteria for systemic therapy. In contrast, interest in evidence-based treatments was low. Searches focused mainly on home remedies (44.5%), while biologics accounted for only 0.4%. CONCLUSIONS Future information campaigns and educational materials should use the lay term “Schuppenflechte”. Online search behavior reveals potential gaps in awareness of guideline-recommended therapies for psoriasis. These findings highlight the need for better patient-oriented, evidence-based digital education.